X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Applied Molecular Transport
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger December 27, 2023
Details:
Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Applied Molecular Transport
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger September 21, 2023
Details:
Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal and Alzheimer’s disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 02, 2023
Details:
Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Rafael Holdings
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 05, 2023
Details:
Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease and NPC1.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Neurology Product Name: Trappsol Cyclo
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Trappsol® Cyclo™ is a proprietary formulation of hydroxypropyl beta cyclodextrin and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering January 04, 2023
Details:
Trappsol Cyclo (Hydroxypropyl beta cyclodextrin), It take the place of defective NPC1 protein and effectively manages cholesterol transportation, by capturing cholesterol with its cyclic structure, within the cell and transports it out of the cell.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
Trappsol® Cyclo™ is a proprietary formulation of hydroxypropyl beta cyclodextrin and in multiple clinical studies has shown encouraging results to effectively manage the transportation of cholesterol.
Lead Product(s): Hydroxypropyl-Beta Cyclodextrin
Therapeutic Area: Rare Diseases and Disorders Product Name: Trappsol Cyclo
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: H.C. Wainwright & Co.
Deal Size: $4.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
